^
Association details:
Biomarker:No biomarker
Cancer:Peritoneal Cancer
Drug:Rubraca (rucaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Acceptable Recurrence Therapies for…Peritoneal Cancer: Targeted Therapy...Rucaparib